RE:ESMO 2022 - Merck's Keytruda fails in H&N cancer as monotherMarch 21, 2024 - Merck has once again failed to boost the effects of its PD-1 blockbuster Keytruda by adding AstraZeneca’s PARP inhibitor Lynparza. This time in NSCLC.
PD-(L)1 checkpoint inhibitors increasingly appear to require ONCY's pelareorep to stimulate the immune system and to remodel the tumor microenvironment (TME) for the subsequent addtion of PD-(L)1 checkpoint inhibitors for these CPI's to become effective.
The same applies to antibody-drug conjugate therapies. ONCY's pelareorep can facilitate ADC therapy, and preclude the cancers from replapsing.
https://www.fiercepharma.com/pharma/mercks-lynparza-keytruda-plan-sputters-2nd-lung-cancer-trial-will-adc-work